PENTA 13

19

Apr, 2010

A Model-based approach to dose selection in early pediatric development

 

Authors: Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O.

Published in: Clinical Pharmacology and Therapeutics, 2010, 87(3):294-302.

Read

19

Apr, 2006

Adherence and acceptability of once daily lamivudine and abacavir in HIV-1 infected children

 

Authors: LeProvost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM on behalf of the PENTA 13 study group.

Published in: PIDJ 2006;25:533-537

Read

19

Jul, 2005

Adherence and acceptability of once daily lamivudine and abacavir in HIV-1 infected children

 

Authors: LeProvost M, Green H, Flynn J, Head S, Clapson M, Lyall H, Novelli V, Farrelly L, Walker AS, Burger DM, Gibb DM on behalf of the PENTA 13 study group.

Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janerio. Poster MoPe9.2C03

19

Apr, 2005

Pharmacokinetics of once versus twice daily lamivudine and abacavir. Simplification of combination treatment in HIV-1 infected children (Penta 13)

 

Authors: Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Khoo S, Gibb DM on behalf of the PENTA 13 study group

Published in: Antivir Ther. 2005; 10:239-246

Read

19

Feb, 2004

Pharmacokinetics (PK) of once daily versus twice daily Lamivudine and Abacavir in HIV-1 infected children: PENTA 13

 

Authors: Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Gibb DM.

Published in: 11th Conference of Retroviruses and Opportunistic Infections, San Francisco, 8-11 February 2004. Poster 934.

Read